Introduction {#Sec1}
============

The eruption of antimicrobial resistance (AMR) has become a serious health concern, making once-treatable pathogenic diseases deadly again and undermining the achievements of current medicine^[@CR1],[@CR2]^. It is also expected that deaths attributable to AMR will exceed 10 million per annum by 2050, from a current baseline of 700,000 deaths annually^[@CR3]^. Therefore, the development of new therapeutic materials and methods to eradicate AMR pathogens is in high demand to overcome the infections caused by such bacteria.

Among such pathogens, opportunistic human pathogens *Staphylococcus* species are the most abundant skin-colonizing Gram-positive bacteria and the most common cause of nosocomial infections and community-associated skin infections, which significantly complicate and increase the cost of medical treatment^[@CR4],[@CR5]^. Among the *Staphylococcus* species, *Staphylococcus aureus* (*S*. *aureus*) has been the subject of most studies owing to its ability to cause severe and life-threatening diseases, such as severe sepsis, pneumonia, toxic shock syndrome, and endocarditis^[@CR6],[@CR7]^. In addition to *S*. *aureus*, other *Staphylococcus* species are also highly detrimental to human health, such as *S*. *epidermidis*, one of the most frequent causes of nosocomial infections present on indwelling devices^[@CR8]--[@CR10]^ and *S*. *saprophyticus*, the second most important cause of urinary tract infections^[@CR11]^. In particular, *S*. *aureus* and *S*. *epidermidis*, methicillin-resistant strains, are now common to hospitals and have spread in a pandemic fashion within the community, producing community-associated methicillin resistant *Staphylococcus* species^[@CR12],[@CR13]^. Many different approaches have been tried to prevent or eradicate the infection of *Staphylococcus* species. One approach is that the development of promising vaccines against *S*. *aureus* species. However, there is no *S*. *aureus* vaccine on the market. There are main reasons why *S*. *aureus* vaccine development has made it to challenge^[@CR14]^. First, the immune responses caused by *S*. *aureus* infection has not been clearly understood. Second, *S*. *aureus* also expresses a large array of virulence factors, resulting any one may not prove effective. Therefore, current trials are focused on multiple antigen preparations. Recently, it was hypothesized that the master mechanism of *S*. *aureus* counteracts may hinder the immunological responses, resulting in failure of target-oriented vaccine development^[@CR15]^. Therefore, the understanding of such mechanisms are the key success for a developing vaccine for the future, but it is still remaining as a challenge. In other aspects, new potential anti-*Staphylococcus* compounds with their plausible action mechanism^[@CR16]--[@CR19]^ and therapeutics^[@CR19],[@CR20]^ have been discovered in recent years, but there is still a high demand for highly potent compounds to specifically target AMR *Staphylococcus* species among bacterial mixtures. Biofilm, a surface‐associated bacterial community surrounded by a self‐produced extracellular matrix^[@CR21]--[@CR25]^ associated with resistance to antimicrobial agents^[@CR26],[@CR27]^. Recently, new materials such as dihydrazone analogues against biofilm forming Gram-negative^[@CR28]^ and benzodioxane midst piperazine decorated chitosan silver nanoparticles (BP\*C\@AgNPs) was controlled the MRSA biofilm^[@CR29]^, still indole and its derivatives have been regarded as interesting heterocyclic antibacterial molecules against AMR bacteria owing to their promising potential to inhibit the formation of biofilm. In addition, the modification of indoles with diverse functional groups would change the efficiency of biofilm inhibition and the antibacterial specificity. For example, C-5/C-7-hydroxylated indoles were more efficient with respect to biofilm inhibition in *Escherichia coli* (*E. coli*)^[@CR30],[@CR31]^. Moreover, various halogenated indoles, especially 5-iodoindole derivatives, potently inhibit biofilm formation of both *E*. *coli* and *S*. *aureus*^[@CR32]^. Alternatively, oxindoles, which are structurally similar to indoles, have diverse pharmacological profiles^[@CR33]--[@CR35]^ and are the most recent synthetic class of new antibacterial agents. For example, a series of oxindole-based 3(*Z*)-{4-\[4-(arylsulfonyl)piperazin-1-ylbenzylidene\]-1,3-dihydro-2*H*-indol-2-one derivatives exhibited significant antibacterial activity against *S*. *aureus*, *Streptococcus pyrogenes*, *E*. *coli*, and *Pseudomonas* (*P*.) *aeruginosa*^[@CR36]^. Moreover, several pharmacophores combined with a single heterocyclic indole or oxindole molecule can result to an enhanced antibacterial activity. For example, novel heterocyclic spiro-oxindole derivatives were active against *E*. *coli* and *S*. *aureus*, with minimum inhibitory concentrations (MIC) of 500 μg equivalent to that of the standard drug, streptomycin^[@CR37]^. One study reported that a combination of spiro-oxindole, 2-amino-4*H*-pyran, and 1,2,3-triazoles in a single matrix showed good Gram-positive antibacterial activity against *S*. *aureus* (MIC = 32--256 μg/mL); however, none of the compounds affected Gram-negative bacteria (*E*. *coli* and *P*. *aeruginosa*)^[@CR38]^. In addition, indole derivatives containing heterocyclic moieties synthesized by using 3-chloro-1*H*-indole-2-carbaldehyde have shown excellent antibacterial activity^[@CR39]^. Based on these previous reports, the antibacterial activity of oxindole derivatives has been observed to enhance and alter for specificity through different functionalization and structural modifications. Therefore, it is of great interest to synthesize and identify highly efficient and selective oxindoles bearing pharmacologically active heterocycles at the 3-position, such as pyrrole, thiophene, and indole moieties, that are probable novel antibacterial agents against health-threatening *Staphylococcus* species.

Based on the above considerations, we have designed and synthesized several different C-3-functionalized oxindoles bearing indole, pyrrole, and thiophene moieties by a novel indium(III)-catalysed reaction (Fig. [1](#Fig1){ref-type="fig"}). In addition, we also screened the synthetic compounds for their anti-*Staphylococcus* activity and synergistic action to existing antibiotics. A preliminary studies of structure-activity relationship (SAR) for the synthesized compounds have also been performed.Figure 1Design strategy for the novel heterocycle-bearing oxindoles. Chemical structures were drawn by ChemDraw Pro 13.0 Suite (PerkinElemer, USA).

Methods {#Sec2}
=======

Materials {#Sec3}
---------

All materials were obtained from commercial suppliers and were used without further purification.

Synthesis of 3-(1H-indol-3-yl)indolin-2-ones KS1 to KS12 {#Sec4}
--------------------------------------------------------

A reaction mixture of the corresponding 3-diazoindolin-2-ones (1, 0.5 mmol) and indoles (2, 0.55 mmol) in 1,2-dichloroethane was stirred at 50 °C for 6 h in the presence of 10 mol% In(OTf)~3~ (Fig. [2](#Fig2){ref-type="fig"}). After completion of the reaction, as indicated by TLC, the reaction mixture was evaporated in a rotary evaporator and the residue was purified by silica gel column chromatography using hexane/ethyl acetate as the eluent to afford the desired products **KS1** to **KS12**.Figure 2One-pot synthesis of 3-indolylindolin-2-ones **KS1**-**KS12**. Chemical structures were drawn by ChemDraw Pro 13.0 Suite (PerkinElemer, USA).

Synthesis of 3-(1-methyl-1H-pyrrol-2-yl)indolin-2-ones KS13 to KS17 and 3-(thiophen-2-yl)indolin-2-ones KS18 to KS20 {#Sec5}
--------------------------------------------------------------------------------------------------------------------

A reaction mixture of the corresponding 3-diazoindolin-2-ones (**1**, 0.5 mmol) and 1-methylpyrrole (**3**, 0.55 mmol) or thiophene (**4**, 0.55 mmol) in 1,2-dichloroethane was stirred at room temperature for 4 h in the presence of 10 mol% In(OTf)~3~ (Fig. [3](#Fig3){ref-type="fig"}). After completion of the reaction, as indicated by TLC, the reaction mixture was evaporated in a rotary evaporator and the residue was purified by silica gel column chromatography using hexane/ethyl acetate as the eluent to afford the desired products **KS13** to **KS17** and **KS18** to **KS20**.Figure 3Synthesis of 3-(1-methylpyrrol-2-yl)indolin-2-ones **KS13**-**KS17** and 3-(thiophen-2-yl)indolin-2-ones **KS18**-**KS20**. Chemical structures were drawn by ChemDraw Pro 13.0 Suite (PerkinElemer, USA).

Characterization {#Sec6}
================

All melting point (MP) was obtained on a Büchi Melting Point B-540 apparatus (Büchi Labortechnik, Switzerland). Mass spectra (MS) were taken in ESI mode on Agilent 1100 LC-MS (Agilent, USA). ^1^H NMR and ^13^C NMR spectra were recorded on Bruker ARX-400, 400 MHz or Bruker ARX-600, 600 MHz spectrometers (Bruker Bioscience, USA) with TMS as an internal standard. Reaction time of the products were monitored by TLC on FLUKA silica gel aluminium cards (0.2 mm thickness) with fluorescent indicator at 254 nm. Column chromatography was run on silica gel. The purity of all the synthesized compounds, determined by their ^1^H and ^13^C NMR spectra, was observed to be 95--99% (see Supporting Information, SI1 for details). In addition, the purity of compound **KS16** was determined by Gas Chromatography (GC) and was found to be 99% (see SI2 for details).

3-(1H-Indol-3-yl)indolin-2-one (KS1) {#Sec7}
------------------------------------

Yield 80% (99 mg), as a red solid: MP 140--142 °C; IR (attenuated total reflectance (ATR)) ν~max~/cm^−1^ 3271, 1700, 1616, 1465, 1329, 1246, 1095, 1042, 805, 740, 600, and 550; ^1^H NMR (600 MHz, DMSO-d~6~) δ 11.02 (1H, s), 10.56 (1H, s), 7.37 (1H, d, *J* = 8.4 Hz), 7.28--7.27 (1H, m), 7.22--7.19 (1H, m), 7.06--7.02 (3H, m), 6.95 (1H, d, *J* = 7.2 Hz), 6.91--6.84 (2H, m), 5.01 (1H, s); ^13^C NMR (150 MHz, DMSO-d~6~) δ 177.7, 142.5, 136.5, 130.4, 127.8, 126.7, 126.0, 124.4, 121.4, 121.1, 118.5, 111.6, 110.0, 109.3, 109.2, 44.4; HRMS m/z (M^+^) calculated for C~16~H~12~N~2~O: 248.0950. Found: 248.0951.

3-(1H-Indol-3-yl)-5-methylindolin-2-one (KS2) {#Sec8}
---------------------------------------------

Yield 72% (94 mg), as a white solid: MP 195--197 °C; IR (ATR) ν~max~/cm^−1^ 3400, 3165, 1691, 1600, 1488, 1450, 1266, 1106, 1020, and 745; ^1^H NMR (600 MHz, DMSO-d~6~) δ 11.00 (1H, s), 10.44 (1H, s), 7.36 (1H, d, *J* = 7.8 Hz), 7.28 (1H, d, *J* = 2.4 Hz), 7.04--7.02 (2H, m), 7.00 (1H, d, *J* = 8.4 Hz), 6.87--6.85 (1H, m), 6.84--6.82 (2H, m), 4.86 (1H, s), 2.16 (3H, s); ^13^C NMR (150 MHz, DMSO-d~6~) δ 177.7, 140.0, 136.5, 130.5, 130.2, 128.0, 126.0, 125.0, 124.5, 121.1, 118.6, 118.5, 111.5, 110.1, 109.0, 44.4, 20.6; HRMS m/z (M^+^) calculated for C~17~H~14~N~2~O: 262.1106. Found: 262.1108.

3-(1H-Indol-3-yl)-5-methoxyindolin-2-one (KS3) {#Sec9}
----------------------------------------------

Yield 74% (103 mg), as a yellow solid: MP 205--207 °C; IR (ATR) ν~max~/cm^−1^ 3402, 3169, 2959, 1689, 1605, 1486, 1454, 1306, 1263, 1206, 1100, 1024, 747, 614, 585, and 518; ^1^H NMR (600 MHz, DMSO-d~6~) δ 11.01 (1H, s), 10.37 (1H, s), 7.36 (1H, d, *J* = 8.4 Hz), 7.28 (1H, d, *J* = 1.8 Hz), 7.05--7.03 (2H, m), 6.87--6.85 (2H, m), 6.78 (1H, dd, *J* = 8.4, 1.8 Hz), 6.62 (1H, s), 4.88 (1H, s), 3.61 (3H, s); ^13^C NMR (150 MHz, DMSO-d~6~) δ 177.5, 154.7, 136.5, 136.0, 131.7, 126.0, 124.5, 124.4, 121.1, 118.5, 112.5, 111.4, 111.3, 110.0, 109.5, 55.3, 45.0; HRMS m/z (M^+^) calculated for C~17~H~14~N~2~O~2~: 278.1055. Found: 278.1054.

5-Fluoro-3-(1H-indol-3-yl)indolin-2-one (KS4) {#Sec10}
---------------------------------------------

Yield 60% (80 mg), as a white solid: MP 158--160 °C; IR (ATR) ν~max~/cm^−1^ 3318, 2954, 1708, 1612, 1482, 1394, 1258, 1179, 1101, 1015, 743, 692, and 590; ^1^H NMR (600 MHz, acetone-d~6~) δ 10.22 (1H, s), 9.55 (1H, s), 7.39 (1H, d, *J* = 8.4 Hz), 7.29 (1H, d, *J* = 2.4 Hz), 7.24 (1H, d, *J* = 8.4 Hz), 7.07 (1H, t, *J* = 7.8 Hz), 7.00--6.99 (2H, m), 6.93--6.90 (2H, m), 5.00 (1H, s); ^13^C NMR (150 MHz, acetone-d~6~) δ 178.0, 159.5 (d, *J* = 235.8 Hz), 139.6, 138.0, 133.3 (d, *J* = 8.1 Hz), 127.2, 125.0, 122.4, 119.7 (d, *J* = 5.7 Hz), 114.8 (d, *J* = 23.1 Hz), 113.1 (d, *J* = 25.2 Hz), 112.4, 112.3, 111.1, 110.7 (d, *J* = 8.1 Hz), 45.8; HRMS m/z (M^+^) calculated for C~16~H~11~FN~2~O: 266.0855. Found: 266.0854.

5-Chloro-3-(1H-indol-3-yl)indolin-2-one (KS5) {#Sec11}
---------------------------------------------

Yield 64% (90 mg), as a white solid: MP 170--172 °C; IR (ATR) ν~max~/cm^−1^ 3360, 3130, 1694, 1612, 1459, 1325, 1220, 1136, 1042, 925, and 732; ^1^H NMR (600 MHz, DMSO-d~6~) δ 11.05 (1H, s), 10.67 (1H, s), 7.37 (1H, d, *J* = 7.8 Hz), 7.30 (1H, d, *J* = 2.4 Hz), 7.26 (1H, d, *J* = 8.4 Hz), 7.06 (1H, t, *J* = 7.8 Hz), 7.00 (1H, d, *J* = 8.4 Hz), 6.99 (1H, s), 6.94 (1H, d, *J* = 9.0 Hz), 6.87 (1H, t, *J* = 7.8 Hz), 4.97 (1H, s); ^13^C NMR (150 MHz, DMSO-d~6~) δ 177.3, 141.4, 136.4, 132.6, 127.6, 125.7, 125.4, 124.7, 124.3, 121.2, 118.6, 118.2, 111.7, 110.6, 109.2, 44.4; HRMS m/z (M^+^) calculated for C~16~H~11~ClN~2~O: 282.0560. Found: 282.0562.

7-Chloro-3-(1H-indol-3-yl)indolin-2-one (KS6) {#Sec12}
---------------------------------------------

Yield 77% (109 mg), as a yellowish solid: MP 213--215 °C; IR (ATR) ν~max~/cm^−1^ 3369, 3133, 1697, 1616, 1455, 1322, 1224, 1133, 1098, 1047, 928, 739, 636, and 539; ^1^H NMR (600 MHz, DMSO-d~6~) δ 11.06 (1H, s), 10.97 (1H, s), 7.38 (1H, d, *J* = 8.4 Hz), 7.30 (1H, d, *J* = 1.2 Hz), 7.27 (1H, d, *J* = 7.8 Hz), 7.07--7.03 (2H, m), 6.97 (1H, d, *J* = 7.2 Hz), 6.92 (1H, d, *J* = 8.4 Hz), 6.90--6.87 (1H, m), 5.07 (1H, s); ^13^C NMR (150 MHz, DMSO-d~6~) δ 177.5, 140.2, 136.4, 132.2, 127.7, 125.8, 124.6, 123.0, 122.7, 121.2, 118.6, 118.3, 113.5, 111.6, 109.3, 45.1; HRMS m/z (M^+^) calculated for C~16~H~11~ClN~2~O: 282.0560. Found: 282.0561.

4-Bromo-3-(1H-indol-3-yl)indolin-2-one (KS7) {#Sec13}
--------------------------------------------

Yield 68% (111 mg), as a white solid: MP 216--218 °C; IR (ATR) ν~max~/cm^−1^ 3282, 3115, 3056, 1695, 1607, 1438, 1373, 1243, 1102, 1043, 733, 640, and 563; ^1^H NMR (600 MHz, DMSO-d~6~) δ 11.01 (1H, s), 10.73 (1H, s), 7.35 (1H, d, *J* = 7.8 Hz), 7.27 (1H, d, *J* = 2.4 Hz), 7.19 (1H, t, *J* = 7.8 Hz), 7.07 (1H, d, *J* = 7.8 Hz), 7.04--7.01 (1H, m), 6.97--6.93 (2H, m), 6.83 (1H, t, *J* = 7.2 Hz), 4.88 (1H, s); ^13^C NMR (150 MHz, DMSO-d~6~) δ 176.5, 144.6, 136.3, 130.0, 129.1, 125.8, 125.4, 124.8, 121.0, 119.2, 118.5, 118.1, 111.6, 108.5, 107.7, 45.8; HRMS m/z (M^+^) calculated for C~16~H~11~BrN~2~O: 326.0055. Found: 326.0057.

5-Bromo-3-(1H-indol-3-yl)indolin-2-one (KS8) {#Sec14}
--------------------------------------------

Yield 72% (118 mg), as a white solid: MP 202--204 °C; IR (ATR) ν~max~/cm^−1^ 3280, 3112, 3050, 1698, 1600, 1431, 1378, 1243, 1042, and 730; ^1^H NMR (600 MHz, DMSO-d~6~) δ 11.05 (1H, s), 10.68 (1H, s), 7.39--7.36 (2H, m), 7.30 (1H, d, *J* = 2.4 Hz), 7.10 (1H, s), 7.05 (1H, t, *J* = 7.8 Hz), 7.01 (1H, d, *J* = 7.8 Hz), 6.91--6.87 (2H, m), 4.98 (1H, s); ^13^C NMR (150 MHz, DMSO-d~6~) δ 177.2, 144.8, 136.4, 133.1, 130.4, 127.0, 125.7, 124.7, 121.2, 118.7, 118.2, 113.1, 111.7, 111.2, 109.2, 44.4; HRMS m/z (M^+^) calculated for C~16~H~11~BrN~2~O: 326.0055. Found: 326.0052.

3-(5-Methoxy-1H-indol-3-yl)indolin-2-one (KS9) {#Sec15}
----------------------------------------------

Yield 76% (106 mg), as a white solid: MP 146--148 °C; IR (ATR) ν~max~/cm^−1^ 3201, 2921, 1697, 1616, 1466, 1271, 1211, 1021, 802, 749, and 678; ^1^H NMR (600 MHz, DMSO-d~6~) δ 10.84 (1H, s), 10.52 (1H, s), 7.25 (1H, d, *J* = 9.0 Hz), 7.21 (1H, t, *J* = 7.8 Hz), 7.18 (1H, d, *J* = 1.8 Hz), 7.03 (1H, d, *J* = 6.6 Hz), 6.93 (1H, d, *J* = 7.8 Hz), 6.90 (1H, t, *J* = 6.6 Hz), 6.71 (1H, dd, *J* = 9.0, 1.8 Hz), 6.54 (1H, d, *J* = 1.2 Hz), 4.87 (1H, s), 3.60 (3H, s); ^13^C NMR (150 MHz, DMSO-d~6~) δ 177.7, 152.8, 142.6, 131.6, 130.3, 127.7, 126.4, 124.9, 124.4, 121.4, 112.1, 110.7, 109.6, 109.1, 101.0, 55.1, 44.2; HRMS m/z (M^+^) calculated for C~17~H~14~N~2~O~2~: 278.1055. Found: 278.1054.

3-(5-Fluoro-1H-indol-3-yl)indolin-2-one (KS10) {#Sec16}
----------------------------------------------

Yield 62% (83 mg), as a yellowish solid: MP 152--154 °C; IR (ATR) ν~max~/cm^−1^ 3291, 2921, 2853, 1696, 1620, 1465, 1292, 1230, 1180, 1098, 935, 797, 747, 680, and 596; ^1^H NMR (600 MHz, DMSO-d~6~) δ 11.12 (1H, s), 10.51 (1H, s), 7.36 (1H, dd, *J* = 8.4, 4.2 Hz), 7.31 (1H, s), 7.22 (1H, t, *J* = 7.2 Hz), 7.04 (1H, d, *J* = 7.2 Hz), 6.95--6.93 (1H, m), 6.92--6.88 (2H, m), 6.75 (1H, d, *J* = 8.4 Hz), 5.01 (1H, s); ^13^C NMR (150 MHz, DMSO-d~6~) δ 177.4, 156.5 (d, *J* = 229.8 Hz), 142.5, 133.0, 130.0, 127.8, 126.2, 126.1 (d, *J* = 10.3 Hz), 124.4, 121.4, 112.5 (d, *J* = 9.1 Hz), 110.2 (d, *J* = 4.6 Hz), 109.3, 109.2 (d, *J* = 26.5 Hz), 103.0 (d, *J* = 22.9 Hz), 44.1; HRMS m/z (M^+^) calculated for C~16~H~11~FN~2~O: 266.0855. Found: 266.0856.

5-Methoxy-3-(5-methoxy-1H-indol-3-yl)indolin-2-one (KS11) {#Sec17}
---------------------------------------------------------

Yield 75% (115 mg), as a yellowish solid: MP 208--210 °C; IR (ATR) ν~max~/cm^−1^ 3256, 2924, 1698, 1489, 1280, 1200, 1024, 800, and 605; ^1^H NMR (600 MHz, DMSO-d~6~) δ 10.84 (1H, s), 10.34 (1H, s), 7.25 (1H, d, *J* = 9.0 Hz), 7.19 (1H, d, *J* = 2.4 Hz), 6.85--6.84 (1H, m), 6.78 (1H, dd, *J* = 8.4, 2.4 Hz), 6.72 (1H, dd, *J* = 8.4, 1.8 Hz), 6.63 (1H, s), 6.55 (1H, d, *J* = 1.8 Hz), 4.84 (1H, s), 3.62 (3H, s), 3.60 (3H, s); ^13^C NMR (150 MHz, DMSO-d~6~) δ 177.5, 154.7, 152.8, 136.1, 131.7, 131.6, 126.4, 125.0, 112.5, 112.1, 111.3, 110.7, 109.7, 109.5, 101.0, 55.3, 55.2, 40.0; HRMS m/z (M^+^) calculated for C~18~H~16~N~2~O~3~: 308.1161. Found: 308.1162.

3-(5-Fluoro-1H-indol-3-yl)-5-methoxyindolin-2-one (KS12) {#Sec18}
--------------------------------------------------------

Yield 70% (104 mg), as a yellowish solid: MP 214--216 °C; IR (ATR) ν~max~/cm^−1^ 3414, 3171, 2931, 1689, 1477, 1262, 1200, 1116, 1025, 779, 602, and 509; ^1^H NMR (600 MHz, DMSO-d~6~) δ 11.13 (1H, s), 10.38 (1H, s), 7.37 (1H, dd, *J* = 9.0, 4.2 Hz), 7.34 (1H, d, *J* = 2.4 Hz), 6.92--6.86 (2H, m), 6.81 (1H, d, *J* = 2.4 Hz), 6.79--6.76 (1H, m), 6.66 (1H, s), 4.89 (1H, s), 3.62 (3H, s); ^13^C NMR (150 MHz, DMSO-d~6~) δ 177.4, 158.1 (d, *J* = 229.9 Hz), 154.9, 136.0, 133.2, 131.4, 126.5, 126.2 (d, *J* = 9.9 Hz), 112.8, 112.6, 111.4, 110.3 (d, *J* = 4.7 Hz), 109.7, 109.4 (d, *J* = 25.8 Hz), 103.2 (d, *J* = 23.1Hz), 55.4, 44.7; HRMS m/z (M^+^) calculated for C~17~H~13~FN~2~O~2~: 296.0961. Found: 296.0958.

3-(1-Methyl-1H-pyrrol-2-yl)indolin-2-one (KS13) {#Sec19}
-----------------------------------------------

Yield 71% (75 mg), as a brownish solid: MP 130--132 °C; IR (ATR) ν~max~/cm^−1^ 3075, 2927, 1703, 1611, 1467, 1315, 1157, 1088, 870, 711, and 547; ^1^H NMR (600 MHz, CDCl~3~) δ 9.07 (1H, s), 7.15 (1H, t, *J* = 7.2 Hz), 7.11 (1H, d, *J* = 7.8 Hz), 6.95 (1H, t, *J* = 7.8 Hz), 6.83 (1H, d, *J* = 7.8 Hz), 6.54 (1H, br s), 5.98 (1H, t, *J* = 3.0 Hz), 5.81 (1H, br s), 4.68 (1H, s), 3.50 (3H, s); ^13^C NMR (150 MHz, CDCl~3~) δ 177.8, 141.4, 129.5, 128.4, 128.2, 125.1, 123.6, 122.6, 110.1, 109.0, 107.0, 45.4, 34.2; HRMS m/z (M^+^) calculated for C~13~H~12~N~2~O: 212.0950. Found: 212.0947.

5-Methoxy-3-(1-methyl-1H-pyrrol-2-yl)indolin-2-one (KS14) {#Sec20}
---------------------------------------------------------

Yield 91% (110 mg), as a white solid: MP 204--206 °C; IR (ATR) ν~max~/cm^−1^ 3200, 2990, 1692, 1612, 1480, 1315, 1092, and 806; ^1^H NMR (600 MHz, DMSO-d~6~) δ 10.32 (1H, s), 6.82--6.78 (2H, m), 6.69--6.68 (2H, m), 5.89 (1H, t, *J* = 3.0 Hz), 5.62 (1H, br s), 4.92 (1H, s), 3.55 (3H, s), 3.35 (3H, s); ^13^C NMR (150 MHz, DMSO-d~6~) δ 176.2, 154.8, 135.8, 130.0, 127.1, 123.0, 113.0, 111.4, 109.7, 107.4, 106.3, 55.4, 45.0, 33.7; HRMS m/z (M^+^) calculated for C~14~H~14~N~2~O~2~: 242.1055. Found: 242.1056.

4-Chloro-3-(1-methyl-1H-pyrrol-2-yl)indolin-2-one (KS15) {#Sec21}
--------------------------------------------------------

Yield 68% (84 mg), as a white solid: MP 116--118 °C; IR (ATR) ν~max~/cm^−1^ 3194, 2903, 2805, 1689, 1625, 1480, 1315, 1149, 1082, and 812; ^1^H NMR (600 MHz, DMSO-d~6~) δ 10.66 (1H, s), 7.25 (1H, t, *J* = 7.8 Hz), 6.98 (1H, d, *J* = 8.4 Hz), 6.86 (1H, d, *J* = 7.2 Hz), 6.67 (1H, br s), 5.87 (1H, t, *J* = 3.0 Hz), 5.52 (1H, br s), 4.99 (1H, s), 3.59 (3H, s); ^13^C NMR (150 MHz, DMSO-d~6~) δ 175.4, 144.4, 130.0, 129.8, 126.2, 125.0, 122.7, 122.0, 108.2, 107.0, 106.4, 44.2, 33.7; HRMS m/z (M^+^) calculated for C~13~H~11~ClN~2~O: 246.0560. Found: 246.0562.

4-Bromo-3-(1-methyl-1H-pyrrol-2-yl)indolin-2-one (KS16) {#Sec22}
-------------------------------------------------------

Yield 64% (93 mg), as a white solid: MP 208--210 °C; IR (ATR) ν~max~/cm^−1^ 3160, 2912, 2855, 1695, 1621, 1487, 1313, 1152, 1092, and 812; ^1^H NMR (600 MHz, DMSO-d~6~) δ 10.64 (1H, s), 7.18 (1H, t, *J* = 7.2 Hz), 7.12 (1H, d, *J* = 7.2 Hz), 6.88 (1H, d, *J* = 7.8 Hz), 6.67 (1H, t, *J* = 2.4 Hz), 5.81 (1H, t, *J* = 2.4 Hz), 5.49 (1H, br s), 4.91 (1H, s), 3.59 (3H, s); ^13^C NMR (150 MHz, DMSO-d~6~) δ 175.3, 144.5, 130.1, 128.4, 127.6, 125.1, 124.9, 122.6, 118.9, 108.6, 106.5, 45.5, 33.7; HRMS m/z (M^+^) calculated for C~13~H~11~BrN~2~O: 290.0055. Found: 290.0058.

5-Bromo-3-(1-methyl-1H-pyrrol-2-yl)indolin-2-one (KS17) {#Sec23}
-------------------------------------------------------

Yield 82% (119 mg), as a white solid: MP 112--114 °C; IR (ATR) ν~max~/cm^−1^ 3180, 2905, 2845, 1698, 1608, 1475, 1330, 1169, 1080, and 801; ^1^H NMR (600 MHz, DMSO-d~6~) δ 10.63 (1H, s), 7.41 (1H, dd, *J* = 7.8, 2.4 Hz), 7.18 (1H, s), 6.85 (1H, d, *J* = 8.4 Hz), 6.71 (1H, t, *J* = 2.4 Hz), 5.90 (1H, t, *J* = 3.0 Hz), 5.62 (1H, br s), 5.03 (1H, s), 3.54 (3H, s); ^13^C NMR (150 MHz, DMSO-d~6~) δ 176.0, 142.0, 131.4, 130.8, 127.3, 126.4, 123.1, 113.2, 111.4, 107.5, 106.4, 44.5, 33.7; HRMS m/z (M+) calculated for C~13~H~11~BrN~2~O: 290.0055. Found: 290.0058.

3-(Thiophen-2-yl)indolin-2-one (KS18) {#Sec24}
-------------------------------------

Yield 75% (81 mg), as a brownish solid: MP 140--142 °C; IR (ATR) ν~max~/cm^−1^ 3363, 2928, 1698, 1608, 1461, 1261, 1104, 840, 731, and 563; ^1H^NMR (600 MHz, CDCl~3~) δ 9.25 (1H, s), 7.20 (1H, d, *J* = 7.8 Hz), 7.18--7.16 (2H, m), 6.98--6.94 (2H, m), 6.92--6.90 (1H, m), 6.85 (1H, d, *J* = 7.8 Hz), 4.80 (1H, s); ^13^C NMR (150 MHz, CDCl~3~) δ 177.5, 141.4, 137.6, 128.7, 127.0, 126.2, 125.3, 125.2, 122.7, 122.6, 110.3, 47.6; HRMS m/z (M^+^) calculated for C~12~H~9~NOS: 215.0405. Found: 215.0406.

5-Chloro-3-(thiophen-2-yl)indolin-2-one (KS19) {#Sec25}
----------------------------------------------

Yield 78% (98 mg), as a yellowish solid: MP 155--157 °C; IR (ATR) ν~max~/cm^−1^ 3034, 2921, 2855, 1701, 1619, 1467, 1307, 1228, 1067, 791, 701, 662, and 556; ^1^H NMR (600 MHz, CDCl~3~) δ 9.32 (1H, s), 7.19 (1H, t, *J* = 3.6 Hz), 7.17 (1H, s), 7.15--7.14 (1H, m), 6.93--6.92 (2H, m), 6.77 (1H, d, *J* = 8.4 Hz), 4.80 (1H, s); ^13^C NMR (150 MHz, CDCl~3~) δ 177.2, 140.0, 136.6, 130.4, 128.8, 128.1, 127.1, 126.4, 125.6, 125.5, 111.3, 47.7; HRMS m/z (M+) calculated for C~12~H~8~ClNOS: 249.0015. Found: 249.0019.

5-Bromo-3-(thiophen-2-yl)indolin-2-one (KS20) {#Sec26}
---------------------------------------------

Yield 80% (117 mg), as a yellow solid: MP 161--163 °C; IR (ATR) ν~max~/cm^−1^ 3172, 3109, 2922, 2853, 1708, 1680, 1470, 1308, 1218, 1191, 806, 690, and 559; ^1^H NMR (600 MHz, CDCl~3~) δ 9.25 (1H, s), 7.38--7.37 (1H, m), 7.36 (1H, s), 7.26--7.25 (1H, m), 7.02--6.99 (2H, m), 6.97 (1H, d, *J* = 8.4 Hz), 4.87 (1H, s); ^13^C NMR (150 MHz, CDCl~3~) δ 177.0, 140.3, 136.6, 131.7, 130.8, 128.4, 127.1, 126.5, 125.6, 115.4, 111.7, 47.6; HRMS m/z (M^+^) calculated for C~12~H~8~BrNOS: 292.9510. Found: 292.9512.

Antibacterial Activity Studies {#Sec27}
==============================

Bacterial strains {#Sec28}
-----------------

*S*. *aureus* (ATCC 25923), *S*. *epidermidis* (ATCC 12228), *S*. *saprophyticus* (ATCC 15305), *E*. *coli* (ATCC 25922), *P*. *aeruginosa* (ATCC 27853), and Methicillin-resistant *S*. *aureus* (MRSA) strains were isolated from Difco Tryptic Soy Agar (TSA; BD, USA) plates and inoculated in BBL Muller-Hinton Broth (MHB; BD, USA) for the preparation of the inoculum used in the antibacterial activity assays.

Screening of active compounds with anti-*S*. *aureus* activity {#Sec29}
--------------------------------------------------------------

The screening for compounds expressing anti-*S*. *aureus* activity was performed by using a disc diffusion method^[@CR40]^. For all bacterial strains, overnight culture grown in MHB (400 μL) was inoculated into 20 mL of Difco Muller Hinton Agar (MHA; BD, USA) and solidified on petri dishes with a diameter of 90 mm (SPL, Korea). Sterile filter discs (6 mm in diameter; Advantec MFS, Taiwan) were placed on the surface of inoculated agar plates. Compounds, to a final amount of 20 μg, were impregnated by dropping 10 μL of 2 mg/mL stock solution to the sterile filter discs. The plates were then incubated at 37 °C for 24 h, and antibacterial activity was evaluated through the measurement of the diameter of the inhibition zone (mm) by using a transparent ruler. Each compound was analysed a minimum of three times and one representative image was presented.

Validation of MRSA strains {#Sec30}
--------------------------

MRSA strains were purchased from CCARM (Culture Collection of Antimicrobial Resistant Microbes; [www.ccarm.or.kr](http://www.ccarm.or.kr)). The verification of strains was performed in two independent experiments. First, assay plates for both six individual MRSA strains and *S*. *aureus* (ATCC 25923) were prepared as described in disc diffusion method and the susceptibility to oxacillin was determined by using an E-test Oxacillin (BioMérieux, France). Second, *S*. *aureus* strains were subjected to PCR amplification for the detection of *mec*A gene in accordance with a previous report^[@CR41]^. The PCR protocol was performed in a total 20 μL volume using 2x Quick Taq mix (Toyobo, Japan). The PCR program was conducted with initial denaturation at 94 °C for 3 min, followed by 28 cycles of 94 °C for 30 s, 55 °C for 30 s, and 68 °C for 30 s, and ended with a final extension at 68 °C for 5 min. The PCR product was electrophoresed on 2% agarose gel and imaged with an E-Graph Gel Documentation System (Atto, Japan). Synthesized primers mecA-F (5′-GTAGAAATGACTGAACGTCCGATGA-3′) and mecA-R (5′-CCAATTCCACATTGTTTCGGTCTAA-3′) were used in the amplification, which produced a PCR amplicon of 310 bp in size.

Determination of MIC {#Sec31}
--------------------

Microbroth dilution MIC testings were performed^[@CR42]^. Briefly, fresh overnight cultured cells were grown until absorbance at 600 nm (A~600~) value of 0.5 was reached and the 500-fold diluted cells were inoculated into 200 μL of MHB in 96-well plates (SPL, Korea) and cultured cells for 16 h at 37 °C with shaking at 250 rpm by using an Incu-Mixer MP (Benchmark Scientific, USA). The MIC value is defined as the minimal concentration of chemical or antibiotic that reduced the turbidity of non-treated bacterial inoculum to 90% after overnight incubation and determined as follows: A~600~ of individual cells grown in 96-well plates was measured using a SPECTROstar Nano (BMG LABTECH, Germany) and MIC values were calculated from the plots of A~600~ vs. the concentrations of compounds. The representative MIC values of at least five independent experiments were shown. All statistical analyses were performed by using SigmaStat (Ver. 4.0) (Systat Software, Inc., USA). P-values of \<0.05 were considered to indicate statistically significant difference.

Screening for antibiotics that exhibit synergistic effects with KS16 {#Sec32}
--------------------------------------------------------------------

To evaluate the combinatorial activity of **KS16** with available antibiotics, 5 μL of DMSO or **KS16** (final concentration, 2.5 μg/mL) was added to 195 μL of Muller Hinton broth inoculated with ATCC 25923 cells in a Sensititre Gram-positive MIC plate (EUST, Thermo Scientific, USA) and determined MIC by the microbroth dilution method, as described above, with the addition of AlamarBlue cell viability reagent (Thermo Scientific, USA) to allow the detection of bacterial growth in accordance with the manufacturer's instructions. Therefore, the final concentrations of the working MIC plates were diluted to one-fourth of that in the original EUST plates.

Determination of synergistic action of compounds to antibiotics {#Sec33}
---------------------------------------------------------------

The fractional inhibitory concentration indices (FICIs) of the designed combinations against *S*. *aureus* were determined by using checkerboard assays, as previously described^[@CR43]^ under the same conditions used to screening the antibiotics to evaluate the combinatorial activity between antibiotics and selected compounds.

Characterization of proteins affected by KS16 {#Sec34}
---------------------------------------------

Total cellular proteins extracted from ATCC25923 cells (1 × 10^9^) treated with different concentrations of **KS16** in 96-well plates were resolved in 12% TGX strain-free gels (Bio-Rad), followed by imaging with ChemiDoc-MP (Bio-Rad). Amounts of protein bands migrated on the gel was analyzed with Image Lab Software (v. 5.2.1; Bio-Rad, USA). For peptide mass fingerprinting (PMF), gels were stained with Brilliant Blue R (Sigma-Aldrich, USA) and interesting protein bands were excised from the gel, followed by subjecting them to in-gel trypsin digestion as described^[@CR44]^. Then, the in-gel digested sample was subjected to MALDI-TOF MS (Microflex LRF 20, Bruker, USA) as previously described^[@CR45]^. Spectra were acquired from 300 shots per spectrum in the m/z range of 600--3,000 and calibrated by two-point internal calibration using trypsin auto-digestion peaks (m/z = 842.5099 and 2211.1046). The processing and peak picking of the spectra were automatically carried out using Flex analysis software v3.0. Threshold used for peak-picking was as follows: 500 for minimum resolution of monoisotopic mass and 5 for S/N. The MS/MS database search was conducted in NCBInr and Swiss-databases using the online MS/MS ion search software, Mascot (<http://www.matrixscience.com/>) with subsequent parameters: trypsin as the cleaving enzyme, a maximum of one missed cleavage, iodoacetamide (Cys) as a complete modification, oxidation (Met) as a partial modification, monoisotopic masses, and a mass tolerance of ±0.1 Da. PMF acceptance criteria is probability scoring.

Cytotoxicity assay {#Sec35}
------------------

The cytotoxicity assay was performed as described in a previous report^[@CR46]^ against human primary skin fibroblast cells (ATCC CRL 2097, USA) with approximately 5 × 10^3^ cells/well in 96-well tissue culture plates (Thermo Scientific, USA). The cells with media containing **KS16** in indicated concentrations were incubated at 37 °C for 24 and 48 h, respectively. Afterwards, one tenth of a total volume of CCK-8 solution was added to each well and the plate was incubated at 37 °C for 3 h. A~450~ was measured by SpectraMax M3 Multi-Mode Microplate Reader (Molecular devices, USA). Percentage viability of **KS16**-treated human fibroblasts to control was presented. All statistical analyses were performed by using SigmaStat (Ver. 4.0) (Systat Software, Inc., USA).

Results and Discussion {#Sec36}
======================

Chemistry {#Sec37}
---------

The 3-indolylindolin-2-ones **KS1**-**KS12** were synthesized by novel indium (III)-catalysed reaction of the corresponding 3-diazoindolin-2-ones **1** with indoles **2** as one-pot procedure (Fig. [2](#Fig2){ref-type="fig"}). Treatment of **1a** with **2a** using 10 mol% of In(OTf)~3~ as a catalyst in 1,2-dichloroethane at 50 °C for 6 h produced **KS1** in 80% yield. The substrates bearing electron-withdrawing and -donating groups were well-tolerated and the desired products were obtained. For example, the reactions of **1b** or **1c** bearing electron-donating groups 5-Me and 5-OMe with **2a** provided **KS2** and **KS3** in 72 and 74% yield, respectively, whereas reactions of diazo compounds **1d**--1H bearing electron-withdrawing groups, 5-F, 5-Cl, 7-Cl, 4-Br, and 5-Br, with **2a** afforded the desired products **KS4**-**KS8** in 60--77% yield. Inspired by these results, we investigated the possibility of utilizing substituted indoles in our synthetic approach. Treatment of **1a** with 5-methoxy-1*H*-indole (**2b**) bearing an electron-donating group in 1,2-DCE at 50 °C for 6 h afforded product **KS9** in 76% yield and combination with 5-fluoro-1*H*-indole (**2c**) bearing an electron-withdrawing group provided **KS10** in 62% yield. Additional reactions of **1c** with **2b** or **2c** led to the desired products **KS11** and **KS12** in 75 and 70% yield, respectively.

Encouraged by these results, further indolin-2-ones **KS13**-**KS20** bearing 1-methylpyrrol-2-yl and thiophen-2-yl group at the 3-position were synthesized starting from 3-diazoindolin-2-ones **1** and 1-methylpyrrole (**3**) or thiophene (**4**) (Fig. [3](#Fig3){ref-type="fig"}). Treatment of **1a** with **3** in the presence of 10 mol% In(OTf)~3~ in 1,2-DCE at room temperature for 4 h afforded the expected product **KS13** in 71% yield. Additional reaction of **1b** bearing an electron-donating group with **3** produced **KS14** in 91% yield and combination of **1g**-**1i** with **3** afforded the corresponding products **KS15**-**KS17** in 64--82% yield. Meanwhile, further coupling reactions of **1a**, **1e**, or 1H with thiophene (**4**) afforded desired products **KS18**-**KS20** in 75--80% yield. All synthetic compounds **KS1** to **KS20** were characterized by the analysis of their spectral data.

Screening of oxindole derivatives as anti-*S*. *aureus* agents {#Sec38}
--------------------------------------------------------------

The newly synthesized heterocyclic indolin-2-ones were next evaluated for their antibacterial activity against *S*. *aureus* by using the disc diffusion method. The anti-*S*. *aureus* activity for the 20 individual compounds (**KS1** to **KS20**) evaluated showed that 14 chemicals produced a clear zone of inhibition against *S*. *aureus* (Figs [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}). Among them, five compounds (**KS15**, **KS16**, **KS17**, **KS19**, and **KS20**) that produced a clear zone of \>10 mm were selected as the target compounds (Figs [4](#Fig4){ref-type="fig"}, [5A](#Fig5){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}). To demonstrate the enhanced antibacterial activity of the synthesized compounds, we have evaluated the discrete antibacterial activity of the starting materials (1-methylpyrrole, oxindole, or thiophene) used for the synthesis of the active compounds under equal amounts (20 μg). However, none of these substrates resulted in any clear zone of inhibition against *S*. *aureus* at 20 μg (Fig. [5B](#Fig5){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}). To compare the effectiveness of the target compounds to that of the nuclear compounds, different amounts (between 20 and 1,000 μg) of 1-methylpyrrole, oxindole, and thiophene were evaluated for the production of a clear zone. We found that only oxindole at 1,000 μg produced a turbid zone (Fig. [5C](#Fig5){ref-type="fig"}), whereas other compounds did not exhibit such inhibitory activity (Fig. [5D,E](#Fig5){ref-type="fig"}). These results indicated that the newly synthesized chemical compounds were at least \> 50-fold more active than the starting materials. Moreover, the compounds showed the comparable activity to streptomycin, while slightly less active to chloramphenicol, erythromycin, and methicillin (Table [1](#Tab1){ref-type="table"} & Fig. [5F](#Fig5){ref-type="fig"}). From a structural perspective (Fig. [3](#Fig3){ref-type="fig"}), five active compounds (**KS15**, **KS16**, **KS17**, **KS19**, and **KS20**) have common structural features: C-4/C-5-halogenated indolin-2-ones bearing 5-membered heterocycles, 1-methylpyrrol-2-yl or thiophen-2-yl group, at the 3-position. Meanwhile, 3-indolylindolin-2-ones **KS1**-**KS12** were relatively inactive, which indicated that the nature of the functionalization at 3-position was a key component in the regulation of function. Specifically, active **KS15**-**KS17** were either brominated or chlorinated at the 4- or 5-position on the benzene ring of the indolin-2-one moiety, whereas inactive **KS13**-**KS14** were either non-halogenated at 4- or 5-position or methoxy-substituted at 5-position. Hence, halogenation at the 5-position of the indolin-2-one scaffold appears to be an important factor of the activity. This structural effect on the enhanced antibacterial activity was further observed for compounds **KS19** and **KS20** bearing -Br or -Cl group at the 5-position.Figure 4Screening of anti-*S*. *aureus* activity of 20 compounds. Newly synthesized compounds (20 μg) were tested for their individual activity against *S*. *aureus* (ATCC 25923) by using a disc fusion assay. Representative images from n = 3 are shown. The zone of inhibition (mm) was measured and is listed in Table [1](#Tab1){ref-type="table"}. DMSO and Disc were used as negative controls. Agar plates were photographed and one of the representative images from n = 5 were processed in Adobe Illustrator CS6 (v16.0.0, Adobe Systems Inc., USA).Figure 5Comparison of effective chemicals, their synthetic moieties, and commercial antibiotics in expression of anti-*Staphylococcus* activity. Activity of (**A**) five highly active compounds (**KS15**, **KS16**, **KS17**, **KS19**, and **KS20**), (**B**--**E**) parental moieties used for synthesis of above compounds and (**F**) commercial antibiotics (chloramphenicol, methicillin, and streptomycin) against *S*. *aureus*. 20 μg of synthesized chemicals (**A**,**B**,**F**) were used to measure the activity, whereas 20 to 1,000 μg were used to evaluate the activity of the substrates. (**C**--**E**) Agar plates were photographed and one of the representative images from n = 5 were processed in Adobe Illustrator CS6 (v16.0.0, Adobe Systems Inc., USA).Table 1Evaluation of anti-*S*. *aureus* activity of target compounds, their parental moieties, and commercial antibiotics^*a*^.CompoundSize of zone, mmDMSONDChloramphenicol20.0 ± 0.7Methicillin24.2 ± 0.8Streptomycin15.8 ± 0.8IndoleNDOxindoleNDThiopheneND1-MethylpyrroleND**KS1**9.1 ± 0.2**KS2**9.2 ± 0.3**KS3**8.0 ± 0.4**KS4**9.2 ± 0.7**KS5**9.4 ± 0.5**KS6**8.9 ± 0.5**KS7**8.4 ± 0.2**KS8**9.1 ± 0.2**KS9**ND**KS10**9.5 ± 0.3**KS11**ND**KS12**ND**KS13**ND**KS14**ND**KS15**12.5 ± 0.8**KS16**12.5 ± 0.9**KS17**12.1 ± 0.8**KS18**ND**KS19**11.2 ± 0.4**KS20**11.4 ± 0.7^a^Zone of inhibition (Figs [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"}) for individual compounds against S. aureus (ATCC 25923) is listed. The values shown are averaged from n = 3. Equal amounts of each compound (20 μg) resuspended in DMSO were used in the assays. ND indicates that clear zone was not observed.

In general, the SAR results indicated that heterocyclic indolin-2-ones **KS13**-**KS20** bearing 1-methylpyrrol-2-yl or thiophen-2-yl group at the 3-position on the indolin-2-one moiety and the halogenation at the 4- or 5-position on the benzene ring of the oxindole moiety significantly influenced their anti-*S*. *aureus* activities.

Determination of MIC of compounds against *S*. *aureus* {#Sec39}
-------------------------------------------------------

We further evaluated the anti-*S*. *aureus* activity of the target compounds by determining the MIC for different concentrations of **KS15**, **KS16**, **KS17**, **KS19**, and **KS20** in comparison to chloramphenicol, methicillin, and streptomycin as control antibiotics. We found that the MIC values for **KS15**, **KS16**, **KS17**, **KS19**, and **KS20** were 6.38, 6.40, 8.72, 9.07, and 8.87 μg/mL, respectively (Fig. [6A,B](#Fig6){ref-type="fig"}), whereas the MIC value for chloramphenicol, methicillin, and streptomycin, was 4.60, 4.07, and 1.73 μg/mL, respectively. Owing to the lower MIC value of **KS15** and **KS16** compared with **KS17**, the position of the halogen at the 4-position of oxindoles with 1-methylpyrrole or thiophene at 3-position appeared to be the most important moieties for enhancing anti-*S*. *aureus* activity. Moreover, our newly synthesized compounds were comparable with commercial antibiotics, which suggested that our compounds are potentially good candidate for antibiotics.Figure 6Determination of MIC against *S*. *aureus*. Antibacterial activity of the newly synthesized compounds and commercial antibiotics (chloramphenicol, methicillin, and streptomycin) against *S*. *aureus* was determined. (**A**) Effect of cell growth of ATCC25923 strain by different compounds. The cells were grown in 96-well plates with different concentrations of **KS15**, **KS16**, **KS17**, **KS19**, **KS20**, chloramphenicol, methicillin, and streptomycin. Images of 96-wells for individual compounds with indicated concentrations were photographed. One of the representative images from n = 5 were processed in Adobe Illustrator CS6 (v16.0.0, Adobe Systems Inc., USA). (**B**) The mean MIC values of the individual compounds. The data was processed from n = 5.

Specificity of compounds against *Staphylococcus* species {#Sec40}
---------------------------------------------------------

We speculated whether the active compounds selectively inhibited the growth of *S*. *aureus*. To answer this question, we determined the MIC of the compounds against subspecies of *Staphylococcus* such as *S*. *epidermidis* (ATCC 12228) and *S*. *saprophyticus* (ATCC 15305) and compared them with that of chloramphenicol, erythromycin, methicillin, and streptomycin. From the data, we found that all five compounds (**KS15**, **KS16**, **KS17**, **KS19**, and **KS20**) were active against tested species (Fig. [7A,B](#Fig7){ref-type="fig"}) with equivalent or higher efficacy with *S*. *epidermidis* and *S*. *saprophyticus*, respectively, than *S*. *aureus* (Figs [6](#Fig6){ref-type="fig"} and [7A,B](#Fig7){ref-type="fig"}). Meanwhile, commercial antibiotics showed different activity among species. For example, chloramphenicol and methicillin, were found to be active against both *S*. *saprophyticus* and *S*. *epidermidis*, while streptomycin was inactive against *S*. *epidermidis* (MIC \> 20 μg/mL) (Fig. [7A](#Fig7){ref-type="fig"}). Therefore, the experimental results suggest that the heterocyclic oxindole derivatives express a broader and specific range of antibacterial activity against members of the common colonization species of *S*. *aureus* than the control antibiotic, streptomycin.Figure 7Analysis of the specificity of active compounds on Gram-positive and -negative strains. (**A**) Antibacterial activity of **KS15**, **KS16**, **KS17**, **KS19**, **KS20**, and chloramphenicol, methicillin, and streptomycin. The activity was determined with different concentrations of compounds against Gram-positive *S*. *epidermidis* (ATCC 12228) (left) and *S*. *saprophyticus* (ATCC 15305) (right). (**B**) Determination of MIC of compounds. Values indicated were averaged from n = 5. (**C**) Evaluation of antibacterial activity against Gram-negative species. The growth of *E*. *coli* (ATCC 25922) and *P*. *aeruginosa* (ATCC 27853) with different concentrations of **KS15**, **KS16**, **KS17**, **KS19**, **KS20**, chloramphenicol, methicillin, and streptomycin was depicted. Images of 96-wells for individual compounds with indicated concentrations were photographed. In (**A**,**B**) one of the representative images from n = 5 were processed in Adobe Illustrator CS6 (v16.0.0, Adobe Systems Inc., USA).

We further tested whether new compounds are effective against two Gram-negative bacteria. First, *E*. *coli* strain (ATCC 25922) was used to examine the effect of compounds on the inhibition of bacterial growth. As shown in Fig. [7C](#Fig7){ref-type="fig"} (left), all compounds were inactive (MIC \> 20 μg/mL) as methicillin (MIC \> 100 μg/mL) against *E*. *coli* cells, while chloramphenicol and streptomycin showed inhibitory effects. Second, we measured MIC values against *P*. *aeruginosa*, a common interactor with *S*. *aureus* in chronic wounds and other types of infections^[@CR47]--[@CR53]^. As shown in Fig. [7C](#Fig7){ref-type="fig"} (right), the MIC values of all compounds against *P*. *aeruginosa* (ATCC 27853) were \>20 μg/mL, as seen for *E*. *coli*, whereas streptomycin showed inhibitory effects only at 20 μg/mL, but this concentration was regarded as non-effective considering that \<10 μg/mL of compounds was effective against *Staphylococcus* species (Figs [6B](#Fig6){ref-type="fig"} and [7B](#Fig7){ref-type="fig"}). Moreover, chloramphenicol and methicillin showed almost no activity to *P*. *aeruginosa* (MIC \> 100 μg/mL; Fig. [7C](#Fig7){ref-type="fig"}, right). All the above data showed that compounds (**KS15**, **KS16**, **KS17**, **KS19**, and **KS20**) are specific to *Staphylococcus* species and indicated that such compounds could be utilized for the eradication of *Staphylococcus* species as narrow spectrum antibiotics in infections co-colonized with *P*. *aeruginosa* or other Gram-negative bacteria.

Activity of compounds against MRSA strains {#Sec41}
------------------------------------------

We expected that the active compounds would be also effective for the inhibition of clinically-isolated MRSA strains. MRSA strains to be tested were confirmed by PCR for the amplification of the *mecA* gene^[@CR41]^, a defining standard in the determination of the resistance of *S*. *aureus* to methicillin including MIC determination. The data showed that all six MRSA strains tested were much less sensitive than MSSA against oxacillin (Fig. [8A](#Fig8){ref-type="fig"}) and produced a *mecA* PCR product of 533 bp in size (Fig. [8B](#Fig8){ref-type="fig"}). Furthermore, we have determined the MIC for five active compounds (**KS15**, **KS16**, **KS17**, **KS19**, and **KS20**) against MRSA strains. The results showed that MIC values for the compounds against all MRSA strains were between 4.5 and 9.7 μg/mL (Fig. [8C,D](#Fig8){ref-type="fig"}), which were similar or slightly lower than that of ATCC 25923 (MSSA). Interestingly, **KS15** and **KS16** showed stronger activity against MRSA than against MSSA, which suggested that **KS15** and **KS16** might be potential compounds for the eradication of MRSA strains which may have been due to the unique functionalization in comparison to other evaluated compounds. The results can provide further insights on how to alter the antibacterial activity of the heterocyclic-bearing oxindole derivatives with specific functionalization at different positions. Therefore, our compounds may be alternative antibiotics for the specific eradication of both methicillin-susceptible and methicillin-resistant *Staphylococcus* species.Figure 8Activity of compounds against MRSA strains. (**A**) Confirmation of MRSA strains. MIC values for MSSA (ATCC 25923) and six MRSA strains were analyzed by the concentration diffusion assay using an E-test on MHA plate. Arrow indicates the MIC of oxacillin for individual strains. The data shown are representatives of n = 3. (**B**) PCR confirmation of the *mecA* gene. PCR amplification using *mecA*-specific primer sets was performed for MSSA (ATCC 25923, Lane 1) and 6 MRSA strains (Lanes 2--7). M indicates DNA size marker (GeneRuler 100 bp Plus DNA ladder; Thermo Scientific). Asterisk (\*) indicates non-specific PCR product. (**C**) Growth analysis of MRSA strains against compounds and streptomycin. Different concentrations of compounds were added to ATCC 25923 cells and cultured for 24 h. One representative experimental data from n = 5 was shown. (**D**) Determination of MIC. The values (μg/mL) were averaged from n = 5. All photographed images shown in (**A**) to (**C**) were processed in Adobe Illustrator CS6 (v16.0.0, Adobe Systems Inc., USA).

Synergistic action of KS16 with aminoglycosides antibiotics {#Sec42}
-----------------------------------------------------------

The five compounds (**KS15**, **KS16**, **KS17**, **KS19**, and **KS20**) showed comparable activity to *S*. *aureus* species with a commercial antibiotic, streptomycin (Fig. [4](#Fig4){ref-type="fig"} & Table [1](#Tab1){ref-type="table"}). Moreover, above compounds showed specific activity to *Staphylococcus* species unlike streptomycin (Figs [6](#Fig6){ref-type="fig"} and [7](#Fig7){ref-type="fig"}). This indicates that newly synthesized compounds could directly use as specific anti-*S*. *aureus* agents. To understand their plausible mechanisms, we approached to identify synergistic antibiotics that is increased their activities by new active compounds assuming that the antibiotics and compounds inhibit the same pathway for the killing of *S*. *aureus*. To this end, we selected **KS16**, one of the most active compounds in this study, and evaluated its combinatorial action with existing antibiotics planted in a pre-made Sensititre Gram-positive MIC plate (Fig. [9A](#Fig9){ref-type="fig"}) by determining MIC values of with or without 2.5 μg/mL of **KS16**, the concentration at which no killing of *S*. *aureus* was found (Fig. [6](#Fig6){ref-type="fig"}). Results showed that the addition of **KS16** to the antibiotics (ciprofloxacin, gentamicin, kanamycin, and streptomycin) increased the susceptibility to *S*. *aureus* compared with the control sample (Fig. [9B,C](#Fig9){ref-type="fig"}; Table [2](#Tab2){ref-type="table"}). Addition to antibiotics seeded on the pre-made Sensititre Plate, we separately evaluated the effect of **KS16** to the susceptibility to methicillin, an ineffective antibiotic to MRSAs. Neither the increase in MIC values of methicillin itself (2.0 μg/mL) nor the synergistic action by **KS16** was detected (Fig. [9D](#Fig9){ref-type="fig"}). Therefore, **KS16** may not expand the arsenal of therapeutic agents for eradicating MRSAs. Interestingly, all selected antibiotics, except ciprofloxacin, a fluoroquinolone class broad-spectrum antibiotic, are known to work as protein synthesis inhibitors targeting the bacterial ribosome. Among them, the gentamicin and kanamycin susceptibility to *S*. *aureus* was increased to more than 4-fold. To evaluate the effect of potency of the combination of **KS16** and gentamicin or kanamycin in comparison to their individual activities, synergy testing by checkerboard assay was performed and found that combinations of **KS16** with gentamicin or kanamycin expressed FICI of 0.5 (Fig. [9D](#Fig9){ref-type="fig"}), an expected value as synergistic drug combination.Figure 9Synergistic activity of **KS16** to antibiotics. (**A**) Information on antibiotics and the working concentration. Sensititre Gram-positive MIC plate (Cat. No. EUST) with final concentration of individual antibiotics shown. CHL, Chloramphenicol; CIP, Ciprofloxacin; CLI, Clindamycin; ERY, Erythromycin; FOX, Cefoxitin; FUS, Fusidate; GEN, Gentamicin; KAN, Kanamycin; LZD, Linezolid; MUP, Mupirocin; PEN, Penicillin; RIF, Rifampin; SMX, Sulfamethoxazole; STR, Streptomycin; SYN, Quinupristin/Dalfopristin; TET, Tetracycline; TIA, Tiamulin; TMP, Trimethoprim; VAN, Vancomycin; NEG and POS indicate the negative and positive control, respectively. The antibiotics induced by **KS16** are indicated in yellow. (**B**,**C**) Effect of **KS16** on the susceptibility to antibiotics. ATCC 25923 cells were cultured in a Sensititre Gram positive MIC plate (Cat. No. EUST) with (**B**) or without (**C**) **KS16** (2.5 μg/mL). Yellow circle of the plate was indicated MIC for each antibiotic. (**D**) Checkerboard assays for gentamicin, kanamycin, and methicillin. Different concentrations of **KS16** and antibiotics were used to determine the susceptibility of ATCC 25923 cells. The yellow circles indicate the concentrations showing FICI = 0.5. One of representative from n = 3 was shown. All images of (**B**--**D**) were photographed and processed in Adobe Illustrator CS6 (v16.0.0, Adobe Systems Inc., USA).Table 2Synergistic activity of **KS16** on antibiotics.AntibioticsAcronymSubclass (cellular target)MIC (μg/mL)−KS16+KS16CefoxitinFOXβ-lactam (penicillin-binding proteins)22ChloramphenicolCHLAmphenicol (50 S)1616CiprofloxacinCIPFluoroquinolone (DNA gyrase)0.50.25ClindamycinCLILincosamide (50 S)0.1250.125ErythromycinERYMacrolide (50 S)0.50.5FusidateFUSSteroid (EF-G)0.250.25GentamicinGENAminoglycoside (30 S)10.25KanamycinKANAminoglycoside (30 S)41LinezolidLZDOxazolidinone (50 S)\>2\>2MethicillinMETβ-lactam2.02.0MupirocinMUPIsoleucyl t-RNA synthetase0.250.25PenicillinPENβ-lactam (peptidoglycan)0.0630.063Quinupristin/DalfopristinSYNLincosamide (50 S)0.250.25RifampinRIFRifampicin (RNA polymerase)0.0150.015StreptomycinSTRAminoglycoside (30 S)84SulfamethoxazoleSMXSulphonamide (Dihydropteroate synthase, DHPS)6464TetracyclineTETTetracycline (30 S)0.50.5TiamulinTIAPleuromutilin (50 S)11TrimethoprimTMPDihydrofolate reductase22VancomycinVANGlycopeptide (cell wall)22Sensititre Gram-positive MIC plate (Cat. No. EUST) except methicillin was used to determine the MIC value (μg/mL). Five independent experiments were performed and reproducible MIC values are listed in the Table. Antibiotics that induced activity through **KS16** are indicated in red. The MIC values decreased by **KS16** are indicated in red.

Increased cellular level of autolysin by KS16 {#Sec43}
---------------------------------------------

Checkerboard assays indicate that **KS16** is a compound for the synergistic combination with gentamicin and kanamycin by sharing the part of cellular targets or pathways for the antibacterial action by gentamicin and kanamycin. Second possibility is that **KS16** increases the permeability for the entry into ribosome targeting antibiotics as reported on the combination of gentamicin and vancomycin although the exact mechanism of synergistic combination has not been verified^[@CR54]^. In opposite to broad-spectrum activity of gentamicin and kanamycin to multiple species^[@CR55]^, **KS16** may target gene product(s) only presented within *S*. *aureus* to function as both antibacterial and synergistic agent with high specificity.

Because **KS16** showed the synergy to antibiotics modulating protein synthesis (Fig. [9](#Fig9){ref-type="fig"}) we assumed that the protein composition in *S*. *aureus* cells is changed by **KS16**. To verify this hypothesis, total proteins from *S*. *aureus* cultures treated with **KS16** of sublethal concentrations (0 to 5 μg/mL) were compared to that of control sample. Interestingly, we found that a protein band migrating \~150 kDa (band ***A***) on SDS-PAGE gel was increased to 4.72-fold by **KS16** with concentration-dependent manner (Fig. [10A](#Fig10){ref-type="fig"}). To characterize the protein MALDI-TOF/peptide mass fingerprinting (PMF) was further performed (Fig. [10B](#Fig10){ref-type="fig"}). By Mascot and Swiss-Prot analysis of trypsin-treated fragments the protein from band ***A*** was denoted as mannosyl-glycoprotein endo-β-N-acetylglucosamidase (EC 3.2.1.96), also known as autolysin (Atl) by sequence similarity (Fig. [10C](#Fig10){ref-type="fig"}). The Atl is a bifunctional protein originally produced as a 138-kDa precursor form and processed to generate mature 62-kDa amidase (AM) and 51-kDa glucosamidase (GM) domains by sequencially^[@CR56]--[@CR58]^.Figure 10Characterization of protein affected by **KS16**. (**A**) Analysis of total cellular proteins from ATCC 25923 cells (1 × 10^9^) treated with different concentrations of **KS16**. Total cellular proteins were resolved on 12% TGX stain-free gels and imaged. The ratio of *A* was calculated using Image Lab Software (Bio-Rad). One of the representative data from n = 3 was shown. (**B**) MALDI-TOF/MS spectrum of band *A*. Arrows indicate the peptide fragments obtained. (**C**) Identification of autolysin protein. Analysis of peptide fragments using Mascot and Swiss-Prot identified that peptides sequences are matching to autolysin protein derived from *Staphylococcus aureus subsp*. *aureus* CIGC341D. Amino acid sequences were taken from NCBIprot database (GenBank: EHT86028.1). Bold underlined sequences (29% coverage) represent peptides matched with autolysin. All images were processed in Adobe Illustrator CS6 (v16.0.0, Adobe Systems Inc., USA).

In functional aspects, Atl is known as a peptidoglycan hydrolase involved in bacterial cell wall degradation through trimming of peptidoglycan and the separation of the daughter cells after division^[@CR59],[@CR60]^. Moreover, the protein is involved in the initial perforation of the cell wall during the autolysis of penicillin-treated *S*. *aureus*^[@CR61]^. Therefore, our results suggest that **KS16** seems to function as an anti-*S*. *aureus* by activating the degradation of peptidoglycan layers of target cells and/or perforation of the cell wall. However, future studies are required to understand how **KS16** showed the synergistic activity to antibiotics related to protein synthesis and how **KS16** selectively affected to the viability of *Staphylococcus* species. For this purpose, profiling analyses of both total RNAs and proteins by high-throughput techniques such as RNA-sequencing and proteomics are required. Such studies will broaden the usage of heterocyclic oxindole compounds as new lead molecules with greater activity and specificity for the eradication of *Staphylococcus* species.

Cytotoxicity of KS16 {#Sec44}
--------------------

For the evaluation of cytotoxicity of **KS16**, human skin fibroblast cell (CRL 2097) was selected in the aspect that one of colonization sites for *S*. *aureus* is skin tissues^[@CR62]^. The cytotoxicity of **KS16** with a range of increasing concentrations (0 to 20 μg/mL) after 24 and 48 h of incubation was determined using the CCK-8 assay. Data showed that **KS16** at MIC level (4.5 to 6.4 μg/mL) against *Staphylococcus* species including MRSAs did not exhibit any cytotoxicity (Fig. [11](#Fig11){ref-type="fig"}). Moreover, even at 20 μg/mL, which is 3.1- to 4.4-fold of MIC value did not exhibit significant cytotoxicity. This indicates that **KS16** could lead to possible non-toxic anti-MRSA application for skin infection.Figure 11Cytotoxicity of assays. Cell viability of human fibroblasts presented as percentage of control after 24 to 48 h exposure to different concentrations of **KS16**. The data represent the average values of n = 3. \* and \*\* Indicate P \< 0.05 and P \< 0.01, respectively. The image was processed in Adobe Illustrator CS6 (v16.0.0, Adobe Systems Inc., USA).

Conclusion {#Sec45}
==========

In summary, we have designed and synthesized diverse oxindoles bearing 3-heterocycles by indium (III)-catalysed reaction of 3-diazoindolin-2-ones and indoles, 1-methylpyrrole, or thiophene. Among the synthesized compounds **KS15**, **KS16**, **KS17**, **KS19**, and **KS20** were the most active compounds with high specificity against various *Staphylococcus* species including MRSA with equivalent or superior activity to streptomycin. The study on synergistic activity of **KS16** with existing antibiotics indicates that **KS16** increased the susceptibility of *S*. *aureus* to ciprofloxacin, gentamicin, kanamycin, and streptomycin. Among them, gentamicin and kanamycin exhibited a synergistic combination with **KS16** to *S*. *aureus*. Moreover, the **KS16** increased the cellular level of autolysin (Atl) protein and expressed the antibacterial activity. Finally, the treatment of **KS16** to skin fibroblast cells at the MIC levels used for killing *Staphylococcus* species was non-toxic. All our findings suggest that our newly developed heterocyclic oxindoles are valuable lead antibacterial agents in the eradication of multidrug-resistant *Staphylococcus* species.
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